文献速递心力衰竭与心肌病

转甲状腺素蛋白淀粉样心肌病1年NT-proBNP变化预测死亡

Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy.
PubMed 文献 · Heart · 2021-05-14

这项回顾性观察研究纳入432例未接受疾病修饰治疗的野生型转甲状腺素蛋白淀粉样心肌病(wtATTR-CM)患者,分析诊断后12个月时多项疾病相关指标变化与后续死亡的关系。结果显示,12个月时N末端B型利钠肽原(NT-proBNP)浓度变化是后续死亡的最强预测因子,且独立于其他指标变化及诊断时已知预后变量。

要点

  • 诊断后12个月NT-proBNP变化是wtATTR-CM患者后续死亡的独立预测因子。
  • NT-proBNP每升高500 ng/L,死亡风险独立增加(校正其他变量变化后HR 1.04)。
  • 随访第一年NT-proBNP升高>500、>1000、>2000 ng/L者分别占45%、35%、16%。

核心结论

  • 随访第一年NT-proBNP浓度变化是wtATTR-CM死亡的强力独立预测因子。

研究设计与样本

  • 回顾性观察研究,纳入英国国家淀粉样变性中心诊断的432例wtATTR-CM患者,均未接受疾病修饰治疗。
  • 采用Cox回归分析诊断至12个月时多种疾病相关变量变化与12个月时间点起死亡的关系。

主要发现

  • 12个月NT-proBNP变化(∆NT-proBNP)是后续死亡的最强预测因子。
  • 校正其他疾病相关变量变化后,NT-proBNP每升高500 ng/L的HR为1.04(95%CI 1.01–1.07),p=0.003。
  • 校正诊断时一系列已知预后变量后,NT-proBNP每升高500 ng/L的HR为1.07(95%CI 1.02–1.13),p=0.007。
  • 随访第一年NT-proBNP升高>500、>1000、>2000 ng/L者分别占45%、35%、16%。

临床怎么用

  • 对wtATTR-CM患者,可在诊断后第一年动态监测NT-proBNP变化以辅助预后评估。

局限性

  • 为回顾性观察研究,患者来自单一国家淀粉样变性中心,且均未接受疾病修饰治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) is a progressive and fatal condition. Although prognosis can be determined at the time of diagnosis according to National Amyloidosis Centre (NAC) transthyretin amyloidosis (ATTR) stage, the clinical course varies substantially between individuals. There are currently no established measures of rate of disease progression. Through systematic analysis of functional, biochemical and echocardiographic disease-related variables we aimed to identify prognostic markers of disease progression in wtATTR-CM. METHODS: This is a retrospective observational study of 432 patients with wtATTR-CM diagnosed at the UK NAC, none of whom received disease-modifying therapy. The association between mortality from the 12-month timepoint and change from diagnosis to 12 months in a variety of disease-related variables was explored using Cox regression. RESULTS: Change in N-terminal pro-B-type natriuretic peptide concentration (∆ NT-proBNP) at 12 months from diagnosis was the strongest predictor of ongoing mortality and was independent of both change in other disease-related variables (HR 1.04 per 500 ng/L increase (95% CI 1.01 to 1.07); p=0.003) and a range of known prognostic variables at the time of diagnosis (HR 1.07 per 500 ng/L increase (95% CI 1.02 to 1.13); p=0.007). An increase in NT-proBNP of >500 ng/L, >1000 ng/L and >2000 ng/L during the first year of follow-up occurred in 45%, 35% and 16% of patients, respectively. CONCLUSION: Change in NT-proBNP concentration during the first year of follow-up is a powerful independent predictor of mortality in wtATTR-CM.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Law S, Petrie A, Chacko L, et al. Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. Heart. 2021. PMID: 33990410. doi:10.1136/heartjnl-2021-319063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。